http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106496213-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65583 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 |
| filingDate | 2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106496213-B |
| titleOfInvention | LCL161 prodrug and its preparation method and application |
| abstract | The invention discloses a kind of LCL161 prodrugs and its preparation method and application.The present invention provides LCL161 prodrug shown in general formula I and its pharmaceutically acceptable salts, hydrate or solvate.The preparation method includes: compound L CL161 and R 1 COR 6 、R 3 PhCnCOR 6 Or (OR 4 )(OR 5 )POR 6 Substitution reaction occurs to obtain；Or compound L CL161 and R 2 OCOR 6 Condensation reaction occurs to obtain；Wherein, n, R 1 , R 2 , R 3 , R 4 And R 5 It is identical as the restriction in general formula I；R 6 For halogen, the halogen can choose chlorine or bromine.The invention also discloses application of the compound in the drug as IAPs inhibitor, preparation prevention or treatment IAPs related disease.The present invention provides the prodrugs of a kind of IAPs antagonist LCL161, can be converted into LCL161 in gastric juice, intestinal juice or blood. |
| priorityDate | 2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 143.